Efficacy and Safety of Text Messages Targeting Adherence to Cardiovascular Medications in Secondary Prevention: TXT2HEART Colombia Randomized Controlled Trial

Anderson Bermon, Ana Fernanda Uribe, Paula Fernanda Pérez-Rivero, David Prieto-Merino, Jose Federico Saaibi, Federico Arturo Silva, Diana Ivonne Canon, Karol Melissa Castillo-Gonzalez, Diana Isabel Cáceres-Rivera, Elizabeth Guio, Karen Janneth Meneses-Castillo, Alberto Castillo-Meza, Louise Atkins, Robert Horne, Elizabeth Murray, Norma Cecilia Serrano, Caroline Free, Juan Pablo Casas, Pablo Perel, Anderson Bermon, Ana Fernanda Uribe, Paula Fernanda Pérez-Rivero, David Prieto-Merino, Jose Federico Saaibi, Federico Arturo Silva, Diana Ivonne Canon, Karol Melissa Castillo-Gonzalez, Diana Isabel Cáceres-Rivera, Elizabeth Guio, Karen Janneth Meneses-Castillo, Alberto Castillo-Meza, Louise Atkins, Robert Horne, Elizabeth Murray, Norma Cecilia Serrano, Caroline Free, Juan Pablo Casas, Pablo Perel

Abstract

Background: Atherosclerotic cardiovascular disease (ASCVD) is the leading cause of mortality worldwide, with a prevalence of approximately 100 million patients. There is evidence that antiplatelet agents and antihypertensive medications could reduce the risk of new vascular events in this population; however, treatment adherence is very low. An SMS text messaging intervention was recently developed based on behavior change techniques to increase adherence to pharmacological treatment among patients with a history of ASCVD.

Objective: This study aims to evaluate the efficacy and safety of an SMS text messaging intervention to improve adherence to cardiovascular medications in patients with ASCVD.

Methods: A randomized controlled clinical trial for patients with a prior diagnosis of cardiovascular events, such as acute myocardial infarction, unstable angina, cerebrovascular disease, or peripheral artery disease, in one center in Colombia was conducted. Patients randomized to the intervention arm were assigned to receive SMS text messages daily for the first 4 weeks, 5 SMS text messages on week 5, 3 SMS text messages each in weeks 6 and 7, and 1 SMS text message weekly from week 8 until week 52. In contrast, patients in the control arm received a monthly SMS text message reminding them of the next study appointment and the importance of the study, requesting information about changes in their phone number, and thanking them for participating in the study. The primary endpoint was the change in low-density lipoprotein cholesterol (LDL-C) levels, whereas the secondary endpoints were the changes in thromboxane B2 levels, heart rate, systolic and diastolic blood pressure, medication adherence, cardiac and noncardiac mortality, and hospitalization. Linear regression analyses and bivariate tests were performed.

Results: Of the 930 randomized patients, 805 (86.5%) completed follow-up and were analyzed for the primary endpoint. There was no evidence that the intervention changed the primary outcome (LDL-C levels; P=.41) or any of the secondary outcomes evaluated (all P>.05). There was also no evidence that the intervention was associated with adverse events.

Conclusions: In this study, there was no evidence that a behavior modification intervention delivered by SMS text messaging improved LDL-C levels, blood pressure levels, or adherence at 12 months. More research is needed to evaluate whether different SMS text messaging strategies, including personalized messages and different timings, are effective; future studies should include mixed methods to better understand why, for whom, and in which context (eg, health system or social environment) SMS text messaging interventions work (or not) to improve adherence in patients with ASCVD.

Trial registration: ClinicalTrials.gov NCT03098186; https://ichgcp.net/clinical-trials-registry/NCT03098186.

International registered report identifier (irrid): RR2-10.1136/bmjopen-2018-028017.

Keywords: Colombia; cardiovascular disease; randomized controlled trial; secondary prevention; text messaging.

Conflict of interest statement

Conflicts of Interest: None declared.

©Anderson Bermon, Ana Fernanda Uribe, Paula Fernanda Pérez-Rivero, David Prieto-Merino, Jose Federico Saaibi, Federico Arturo Silva, Diana Ivonne Canon, Karol Melissa Castillo-Gonzalez, Diana Isabel Cáceres-Rivera, Elizabeth Guio, Karen Janneth Meneses-Castillo, Alberto Castillo-Meza, Louise Atkins, Robert Horne, Elizabeth Murray, Norma Cecilia Serrano, Caroline Free, Juan Pablo Casas, Pablo Perel. Originally published in JMIR mHealth and uHealth (https://mhealth.jmir.org), 28.07.2021.

Figures

Figure 1
Figure 1
CONSORT (Consolidated Standards of Reporting Trials) diagram.
Figure 2
Figure 2
Distribution of the MARS-5 scores at baseline. Graphs by Intervention. MARS-5: Medication Adherence Report Scale-5.

References

    1. GBD 2017 Causes of Death Collaborators Global, regional, and national age-sex-specific mortality for 282 causes of death in 195 countries and territories, 1980-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet. 2018 Nov 10;392(10159):1736–88. doi: 10.1016/S0140-6736(18)32203-7.
    1. Roth GA, Johnson C, Abajobir A, Abd-Allah F, Abera SF, Abyu G, Ahmed M, Aksut B, Alam T, Alam K, Alla F, Alvis-Guzman N, Amrock S, Ansari H, Ärnlöv J, Asayesh H, Atey TM, Avila-Burgos L, Awasthi A, Banerjee A, Barac A, Bärnighausen T, Barregard L, Bedi N, Belay Ketema E, Bennett D, Berhe G, Bhutta Z, Bitew S, Carapetis J, Carrero JJ, Malta DC, Castañeda-Orjuela CA, Castillo-Rivas J, Catalá-López F, Choi J, Christensen H, Cirillo M, Cooper L, Criqui M, Cundiff D, Damasceno A, Dandona L, Dandona R, Davletov K, Dharmaratne S, Dorairaj P, Dubey M, Ehrenkranz R, El Sayed Zaki M, Faraon EJ, Esteghamati A, Farid T, Farvid M, Feigin V, Ding EL, Fowkes G, Gebrehiwot T, Gillum R, Gold A, Gona P, Gupta R, Habtewold TD, Hafezi-Nejad N, Hailu T, Hailu GB, Hankey G, Hassen HY, Abate KH, Havmoeller R, Hay SI, Horino M, Hotez PJ, Jacobsen K, James S, Javanbakht M, Jeemon P, John D, Jonas J, Kalkonde Y, Karimkhani C, Kasaeian A, Khader Y, Khan A, Khang Y, Khera S, Khoja AT, Khubchandani J, Kim D, Kolte D, Kosen S, Krohn KJ, Kumar GA, Kwan GF, Lal DK, Larsson A, Linn S, Lopez A, Lotufo PA, El Razek HM, Malekzadeh R, Mazidi M, Meier T, Meles KG, Mensah G, Meretoja A, Mezgebe H, Miller T, Mirrakhimov E, Mohammed S, Moran AE, Musa KI, Narula J, Neal B, Ngalesoni F, Nguyen G, Obermeyer CM, Owolabi M, Patton G, Pedro J, Qato D, Qorbani M, Rahimi K, Rai RK, Rawaf S, Ribeiro A, Safiri S, Salomon JA, Santos I, Santric Milicevic M, Sartorius B, Schutte A, Sepanlou S, Shaikh MA, Shin M, Shishehbor M, Shore H, Silva DA, Sobngwi E, Stranges S, Swaminathan S, Tabarés-Seisdedos R, Tadele Atnafu N, Tesfay F, Thakur JS, Thrift A, Topor-Madry R, Truelsen T, Tyrovolas S, Ukwaja KN, Uthman O, Vasankari T, Vlassov V, Vollset SE, Wakayo T, Watkins D, Weintraub R, Werdecker A, Westerman R, Wiysonge CS, Wolfe C, Workicho A, Xu G, Yano Y, Yip P, Yonemoto N, Younis M, Yu C, Vos T, Naghavi M, Murray C. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017 Jul 4;70(1):1–25. doi: 10.1016/j.jacc.2017.04.052.
    1. Kerr AJ, Broad J, Wells S, Riddell T, Jackson R. Should the first priority in cardiovascular risk management be those with prior cardiovascular disease? Heart. 2009 Feb;95(2):125–9. doi: 10.1136/hrt.2007.140905.
    1. Yusuf S. Two decades of progress in preventing vascular disease. Lancet. 2002 Jul 6;360(9326):2–3. doi: 10.1016/S0140-6736(02)09358-3.
    1. Model List of Essential Medicines, 21st List. World Health Organization. 2019. [2020-01-12]. .
    1. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83. doi: 10.1016/j.jacl.2013.03.001.
    1. Lauffenburger JC, Robinson JG, Oramasionwu C, Fang G. Racial/Ethnic and gender gaps in the use of and adherence to evidence-based preventive therapies among elderly Medicare Part D beneficiaries after acute myocardial infarction. Circulation. 2014 Feb 18;129(7):754–63. doi: 10.1161/CIRCULATIONAHA.113.002658.
    1. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, Gupta R, Kelishadi R, Iqbal R, Avezum A, Kruger A, Kutty R, Lanas F, Lisheng L, Wei L, Lopez-Jaramillo P, Oguz A, Rahman O, Swidan H, Yusoff K, Zatonski W, Rosengren A, Teo KK, Prospective Urban Rural Epidemiology (PURE) Study Investigators Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011 Oct 1;378(9798):1231–43. doi: 10.1016/S0140-6736(11)61215-4.
    1. Haider R, Sudini L, Chow CK, Cheung NW. Mobile phone text messaging in improving glycaemic control for patients with type 2 diabetes mellitus: A systematic review and meta-analysis. Diabetes Res Clin Pract. 2019 Apr;150:27–37. doi: 10.1016/j.diabres.2019.02.022.
    1. Horvath T, Azman H, Kennedy GE, Rutherford GW. Mobile phone text messaging for promoting adherence to antiretroviral therapy in patients with HIV infection. Cochrane Database Syst Rev. 2012 Mar 14;(3):CD009756. doi: 10.1002/14651858.CD009756.
    1. Nglazi MD, Bekker L, Wood R, Hussey GD, Wiysonge CS. Mobile phone text messaging for promoting adherence to anti-tuberculosis treatment: a systematic review. BMC Infect Dis. 2013 Dec 2;13:566. doi: 10.1186/1471-2334-13-566.
    1. Palmer MJ, Henschke N, Villanueva G, Maayan N, Bergman H, Glenton C, Lewin S, Fønhus MS, Tamrat T, Mehl GL, Free C. Targeted client communication via mobile devices for improving sexual and reproductive health. Cochrane Database Syst Rev. 2020 Jul 14;8:CD013680. doi: 10.1002/14651858.CD013680.
    1. Liu X, Lewis JJ, Zhang H, Lu W, Zhang S, Zheng G, Bai L, Li J, Li X, Chen H, Liu M, Chen R, Chi J, Lu J, Huan S, Cheng S, Wang L, Jiang S, Chin DP, Fielding KL. Effectiveness of electronic reminders to improve medication adherence in tuberculosis patients: a cluster-randomised trial. PLoS Med. 2015 Sep;12(9):e1001876. doi: 10.1371/journal.pmed.1001876.
    1. MinTIC. Bogotá: 2020. Jun, [2021-02-02]. Estrategia Integral para mejorar las condiciones de prestación de servicios fijos y móviles en Colombia. .
    1. Adler AJ, Martin N, Mariani J, Tajer CD, Owolabi OO, Free C, Serrano NC, Casas JP, Perel P. Mobile phone text messaging to improve medication adherence in secondary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2017 Apr 29;4:CD011851. doi: 10.1002/14651858.CD011851.pub2.
    1. Abroms LC, Whittaker R, Free C, van Alstyne J, Schindler-Ruwisch JM. Developing and pretesting a text messaging program for health behavior change: recommended steps. JMIR Mhealth Uhealth. 2015 Dec 21;3(4):e107. doi: 10.2196/mhealth.4917.
    1. Bermon A, Uribe-Rodríguez AF, Pérez-Rivero PF, Prieto-Merino D, Cáceres Rivera DI, Guio E, Atkins L, Horne R, Murray E, Serrano Díaz NC, Free C, Perel P, Casas JP. Evaluation of the efficacy and safety of text messages targeting adherence to cardiovascular medications in secondary prevention: the txt2heart Colombia randomised controlled trial protocol. BMJ Open. 2019 Dec 8;9(12):e028017. doi: 10.1136/bmjopen-2018-028017.
    1. Uribe-Rodriguez A, Perez-Rivero P, Free C, Perel P, Murray E, Serrano N. Designing a Text Messaging Program to Increase Adherence to Medication for the Secondary Prevention of Cardiovascular Disease. medRxiv. 2019. [2021-02-20]. .
    1. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Br Med J. 2010 Mar 23;340:c869. doi: 10.1136/bmj.c869.
    1. Chan AH, Horne R, Hankins M, Chisari C. The Medication Adherence Report Scale: a measurement tool for eliciting patients' reports of nonadherence. Br J Clin Pharmacol. 2020 Jul;86(7):1281–8. doi: 10.1111/bcp.14193. doi: 10.1111/bcp.14193.
    1. Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME, Aikens JE, Hunter CM, Velligan DI, Huntley K, Ogedegbe G, Rand CS, Schron E, Nilsen WJ. Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med. 2015 Dec 9;5(4):470–82. doi: 10.1007/s13142-015-0315-2.
    1. Chow CK, Redfern J, Hillis GS, Thakkar J, Santo K, Hackett ML, Jan S, Graves N, de Keizer L, Barry T, Bompoint S, Stepien S, Whittaker R, Rodgers A, Thiagalingam A. Effect of lifestyle-focused text messaging on risk factor modification in patients with coronary heart disease: a randomized clinical trial. J Am Med Assoc. 2015;314(12):1255–63. doi: 10.1001/jama.2015.10945.
    1. Zheng X, Spatz ES, Bai X, Huo X, Ding Q, Horak P, Wu X, Guan W, Chow CK, Yan X, Sun Y, Wang X, Zhang H, Liu J, Li J, Li X, Spertus JA, Masoudi FA, Krumholz HM. Effect of text messaging on risk factor management in patients with coronary heart disease: the chat randomized clinical trial. Circ Cardiovasc Qual Outcomes. 2019 Apr;12(4):e005616. doi: 10.1161/CIRCOUTCOMES.119.005616.
    1. Free C, Knight R, Robertson S, Whittaker R, Edwards P, Zhou W, Rodgers A, Cairns J, Kenward MG, Roberts I. Smoking cessation support delivered via mobile phone text messaging (txt2stop): a single-blind, randomised trial. Lancet. 2011 Jul 2;378(9785):49–55. doi: 10.1016/S0140-6736(11)60701-0.
    1. Haynes RB, Ackloo E, Sahota N, McDonald HP, Yao X. Interventions for enhancing medication adherence. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD000011. doi: 10.1002/14651858.CD000011.pub3.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera